References
- Fonsatti E, Maio M, Altomonte M, . Biology and clinical applications of CD40 in cancer treatment. Semin Oncol 2010;37: 517–523.
- Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–135.
- Hayden MS, Ghosh S. NF-kB in immunobiology. Cell Res 2011;21: 223–244.
- Hömig-Hölzel C, Hojer C, Rastelli J, . Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kB pathway and promotes lymphomagenesis. J Exp Med 2008;205:1317–1329.
- Scielzo C, Apollonio B, Scarfo L, . The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 2011;25:1760–1767.
- Byrd JC, Kipps TJ, Flinn IW, . Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:2136–2142.
- Kato K, Cantwell MJ, Sharma S, . Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998;101:1133–1141.
- Wierda WG, Cantwell MJ, Woods SJ, . CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96: 2917–2924.
- Wierda WG, Castro JE, Aguillon R, . A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 2010;24:1893–1900.